Literature DB >> 9260696

Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.

D Navarro1, E Lennette, S Tugizov, L Pereira.   

Abstract

Sera from patients with primary human cytomegalovirus (HCMV) infections, both acute and convalescent phase, and from HCMV-seropositive healthy subjects were analyzed to determine whether the sera would recognize antigenic domains on HCMV glycoprotein B (gB) that function in virion infectivity and spread of virus from cell to cell. The intact gB molecule, amino-terminal derivatives of different lengths, and internal deletion derivatives were expressed in eukaryotic cells and reacted by immunofluorescence with the sera. All convalescent-phase sera and most sera from healthy seropositive individuals reacted with full-length gB and with an amino-terminal derivative containing 687 amino acids (aa), gB-(1-687); approximately half of the sera recognized an amino-terminal derivative of 447 aa, gB-(1-447), and one-third reacted with the shortest deletion derivative of 258 aa, gB-(1-258). Of the acute-phase sera, 77% recognized intact gB and gB-(1-687), 32% recognized gB-(1-447), and 14% recognized gB-(1-258). Deletion of aa 548 to 618 dramatically reduced the percentage of reactive sera, whereas deletion of aa 411 to 447 had a minor impact on reactivity of sera. To investigate the epitope specificity of human antibodies to gB, we carried out competition experiments between human sera with neutralizing activity and selected monoclonal antibodies (mAbs) to conformational epitopes on gB. We found that antibodies in human sera preclude syncytium formation in UB15-11 glioblastoma cells constitutively expressing gB and compete with certain murine mAbs that block virus entry into cells and transmission of infection from cell to cell. Our results show that HCMV-immune human sera contain antibodies to functional regions on gB, and the abundance of these antibodies in convalescent-phase sera suggests that they may play a central role in limiting dissemination of virus in the host.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9260696

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

1.  An acidic cluster in the cytosolic domain of human cytomegalovirus glycoprotein B is a signal for endocytosis from the plasma membrane.

Authors:  S Tugizov; E Maidji; J Xiao; L Pereira
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Human cytomegalovirus glycoprotein B contains autonomous determinants for vectorial targeting to apical membranes of polarized epithelial cells.

Authors:  S Tugizov; E Maidji; J Xiao; Z Zheng; L Pereira
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

3.  Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum.

Authors:  Daniel J Hackett; Changpin Zhang; Carla Stefanescu; Robert F Pass
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

Review 4.  Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Authors:  Mark R Schleiss
Journal:  Infect Disord Drug Targets       Date:  2011-10

Review 5.  Synthetic DNA approach to cytomegalovirus vaccine/immune therapy.

Authors:  Stephan J Wu; Daniel O Villarreal; Devon J Shedlock; David B Weiner
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 6.  Cytomegalovirus Vaccines: Current Status and Future Prospects.

Authors:  K M Anderholm; C J Bierle; M R Schleiss
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

7.  Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Authors:  Andres G Grandea; Ole A Olsen; Thomas C Cox; Mark Renshaw; Philip W Hammond; Po-Ying Chan-Hui; Jennifer L Mitcham; Witold Cieplak; Shaun M Stewart; Michael L Grantham; Andrew Pekosz; Maki Kiso; Kyoko Shinya; Masato Hatta; Yoshihiro Kawaoka; Matthew Moyle
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-01       Impact factor: 11.205

8.  Prevention of maternal cytomegalovirus infection: current status and future prospects.

Authors:  Jessica L Nyholm; Mark R Schleiss
Journal:  Int J Womens Health       Date:  2010-08-09

9.  Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.

Authors:  Devon J Shedlock; Kendra T Talbott; Stephan J Wu; Christine M Wilson; Karuppiah Muthumani; Jean D Boyer; Niranjan Y Sardesai; Sita Awasthi; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

Review 10.  Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.

Authors:  Robert F Pass
Journal:  J Clin Virol       Date:  2009-07-31       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.